InsightRX vs PrecisePK (2026)
A close comparison. Both run Bayesian dosing and both let a pharmacy see the science behind a dose. InsightRX runs named published population pharmacokinetic models, holds certified Epic marketplace integration, and publishes an analysis of 168,000 treatment courses that compared models across patient groups and changed its default. PrecisePK walks through its computation step by step on its own site. The assurance picture splits the other way from what a buyer might expect. PrecisePK publishes its business associate agreement in full and names SOC 2 Type 2 and ISO/IEC 27001 certification. InsightRX holds HITRUST r2 but states no HIPAA status and publishes no business associate terms.
- The population pharmacokinetic models are named published models, so a pharmacy can read the science behind a dose.
- Its analysis of 168,000 treatment courses compared models across patient groups and changed the default model.
- Integration is certified in the Epic marketplace, and automatic import is limited to the data the dose calculation needs.
- The business associate agreement is published in full at an open URL, so every customer signs the same terms.
- It names SOC 2 Type 2 and ISO/IEC 27001:2022 certification and offers copies on request.
- The computation is walked through in sequence on its own site, from population model through Bayesian updating.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. InsightRX and PrecisePK are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | InsightRX | PrecisePK |
|---|---|---|
| Primary category | Medication Safety & Prescribing | Medication Safety & Prescribing |
| Founded | 2015 | Not recorded |
| Headquarters | San Francisco, California, United States | San Diego, California, United States |
| Website | insight-rx.com | precisepk.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
InsightRX
-
Model / architecture
InsightRX released Gemini 2026.2, an update to the model selection engine in InsightRX Nova that adds a new general adult vancomycin model, McCarthy 2026, plus CKD-EPI eGFR versions of the published models that improved with that input.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
InsightRX builds model informed precision dosing software, which computes an individualized dose for a drug whose therapeutic window is narrow enough that getting it wrong causes harm. The core product, Nova, combines published population pharmacokinetic models with maximum a posteriori Bayesian forecasting: it starts from what is known about how a drug behaves in a population, updates that against the concentrations actually measured in this patient, and returns a regimen.
Source: AI Health Index, September 2026
PrecisePK is Bayesian therapeutic drug monitoring software from Healthware, Inc. in San Diego, with a clinical lineage going back more than thirty years. It began as T.D.M.S. 2000, developed by Philip Anderson, a doctor of pharmacy, with pharmacokinetic consultants, and programmed by Anjum Gupta, a computer scientist, both professors at the University of California, San Diego, and beta tested by the Applied Pharmacokinetics Service at UCSD Medical Center and Rady Children's Hospital.
Source: AI Health Index, September 2026
Questions buyers ask
How do InsightRX and PrecisePK work with the EHR?
The applications are certified in the Epic Showroom with automatic patient data import, certified in the Oracle Cloud Marketplace for Oracle Health, and available for direct integration with MEDITECH Expanse, and the mechanism is SMART on FHIR rather than a proprietary interface, with InsightRX's implementation team validating data flow before go live.
PrecisePK's own material says that when integrated with an EHR the software retrieves patient information from it, and treats integration as a purchasing consideration alongside clinical surveillance tools and reporting compliance. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
Which settings and specialties do InsightRX and PrecisePK cover?
In InsightRX's case, the library covers more than a hundred drugs and therapeutic areas spanning infectious disease, oncology and transplant. Age coverage extends to pediatrics, with a registered randomized pilot in a pediatric intensive care unit dosing vancomycin and amikacin.
For PrecisePK, the product supports therapeutic drug monitoring across the drug classes where measured concentrations guide dosing, with vancomycin dominating current practice and the aminoglycosides and other narrow therapeutic index agents alongside it, and the company states use in all types of patients. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
What evidence is published for InsightRX and PrecisePK?
An independent group publishing in Pharmacotherapy in 2018 compared five Bayesian dose optimizing programs in critically ill patients and found InsightRX the most adaptable and best supported, while ranking another program as the least biased, so the independent comparison did not put this vendor first on accuracy.
Turner and colleagues at Pacific University School of Pharmacy, publishing in Pharmacotherapy in 2018, compared five Bayesian dose optimizing programs and two first order equations for estimating vancomycin area under the curve in critically ill patients, and found PrecisePK the least biased of the group at a median of 5.1 percent. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
How much do InsightRX and PrecisePK leave to the clinician?
For InsightRX, two disclosed design decisions concern what happens when the inputs are bad. Nova flags missing or stale data explicitly in the interface rather than silently computing on it, and pharmacists retain full manual data entry, so a broken feed or a record system outage degrades the workflow rather than blocking patient care.
With PrecisePK, two design choices strengthen the oversight position. The user can either have the software select the pharmacokinetic model that best fits the patient or select it manually, which keeps the single most consequential modeling decision in human hands rather than automating it silently. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
The independent 2018 comparison in Pharmacotherapy included both and did not find the programs equivalent across every measure, so ask each vendor for results on the agents your service doses. Neither holds a device clearance. PrecisePK's independent evidence covers 19 critically ill patients, and it publishes results within that group only. InsightRX compares results across patient groups for vancomycin in adults with a BMI under 40. InsightRX states no HIPAA status.